Robert F. Storey
#123,685
Most Influential Person Now
Researcher
Robert F. Storey's AcademicInfluence.com Rankings
Robert F. Storeycomputer-science Degrees
Computer Science
#5092
World Rank
#5379
Historical Rank
Computer Engineering
#41
World Rank
#42
Historical Rank
Data Science
#76
World Rank
#78
Historical Rank
Computational Linguistics
#625
World Rank
#637
Historical Rank
Download Badge
Computer Science
Robert F. Storey's Degrees
- PhD Computer Science Stanford University
- Masters Computer Engineering University of California, Berkeley
- Bachelors Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Robert F. Storey Influential?
(Suggest an Edit or Addition)Robert F. Storey's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). (2011) (5496)
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes. (2009) (4964)
- ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (2012) (4622)
- [ESC/EAS Guidelines for the management of dyslipidaemias]. (2011) (3612)
- 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. (2020) (3083)
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (3071)
- [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. (2016) (2910)
- Long-term use of ticagrelor in patients with prior myocardial infarction. (2015) (1399)
- ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (1103)
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study (2009) (878)
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial (2010) (764)
- Third universal definition of myocardial infarction. (2012) (751)
- Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation (2019) (698)
- Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study (2010) (628)
- Expert position paper on air pollution and cardiovascular disease. (2015) (597)
- 'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. (2011) (596)
- Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (2014) (550)
- Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. (2007) (519)
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2011) (491)
- Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis (2010) (478)
- Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. (2007) (465)
- Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study (2010) (448)
- Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial (2010) (443)
- The role of platelets in inflammation (2015) (404)
- Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2010) (400)
- Complete Revascularization with Multivessel PCI for Myocardial Infarction. (2019) (399)
- Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. (2009) (388)
- Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. (2010) (356)
- Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (337)
- 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. (2015) (327)
- Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. (2019) (302)
- [2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation]. (2015) (300)
- The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity (2000) (298)
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. (2016) (294)
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial (2011) (268)
- Prehospital ticagrelor in ST-segment elevation myocardial infarction. (2014) (266)
- International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies (2017) (264)
- Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention (2013) (228)
- Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. (2011) (224)
- Antiplatelet agents for the treatment and prevention of atherothrombosis. (2011) (220)
- Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes (2001) (204)
- Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial (2019) (189)
- Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. (2011) (186)
- Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. (2015) (183)
- 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European (2018) (183)
- First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel: The ONSET/OFFSET and RESPOND Genotype Studies (2010) (181)
- Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. (2016) (181)
- Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial (2014) (178)
- Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. (2013) (177)
- Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial (2012) (176)
- Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. (2010) (174)
- Biology and pharmacology of the platelet P2Y12 receptor. (2006) (173)
- Clopidogrel resistance (2004) (169)
- Association of MicroRNAs and YRNAs With Platelet Function. (2016) (169)
- Update on lipids, inflammation and atherothrombosis (2011) (168)
- Inhibition of ADP-induced P-selectin Expression and Platelet-Leukocyte Conjugate Formation by Clopidogrel and the P2Y12 Receptor Antagonist AR-C69931MX but not Aspirin (2002) (162)
- Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel (2014) (161)
- Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention (2018) (156)
- Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor (2005) (156)
- Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. (2016) (145)
- Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease (2002) (143)
- Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study (2013) (142)
- Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial (2013) (137)
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack (2012) (133)
- Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2012) (130)
- Response variability to P2Y12 receptor inhibitors: expectations and reality. (2013) (128)
- Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. (2016) (127)
- Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. (2017) (127)
- The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
- The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. (2011) (116)
- The P2Y 12 receptor as a therapeutic target in cardiovascular disease (2001) (115)
- Effects of P2Y 1 and P2Y 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood (2001) (110)
- Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis (2016) (109)
- Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. (2014) (104)
- Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. (2016) (104)
- Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model (2015) (102)
- Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy (2018) (97)
- Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (96)
- Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial (2014) (96)
- Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. (2016) (96)
- P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction (2015) (95)
- Effect of genetic variations on ticagrelor plasma levels and clinical outcomes. (2015) (94)
- Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease (2013) (93)
- Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium (2022) (92)
- Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. (2012) (88)
- Mimesis and the Human Animal: On the Biogenetic Foundations of Literary Representation (1996) (87)
- The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. (2011) (87)
- Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. (2015) (85)
- Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial (2015) (85)
- Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function (2010) (84)
- Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. (2018) (83)
- Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis (2009) (83)
- Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy (2006) (79)
- Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. (1998) (79)
- Aspirin resistance and diabetes mellitus (2008) (79)
- Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery (2014) (78)
- Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. (2019) (72)
- Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study (2013) (72)
- Effect of P2Y12 inhibitors on inflammation and immunity (2015) (70)
- Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. (2017) (70)
- 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. (2022) (68)
- Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3 (2009) (68)
- Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). (2011) (68)
- Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting. (2013) (67)
- Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses (2011) (66)
- Stent Thrombosis in Patients with Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. (2019) (65)
- Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial. (2019) (64)
- The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial (2014) (63)
- Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. (2005) (61)
- Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention (2016) (60)
- Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (2018) (60)
- The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses (2008) (60)
- Guía de la ESC/EAS sobre el manejo de las dislipemias (2011) (59)
- Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis (2020) (58)
- Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel (2010) (58)
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease (2020) (58)
- PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy (2005) (56)
- Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction (2016) (56)
- Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. (2015) (56)
- Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. (2020) (55)
- Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
- Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. (2012) (54)
- Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology (2015) (54)
- Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. (2018) (53)
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2015) (53)
- Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. (2014) (52)
- Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study (2018) (52)
- Dyspnoea management in acute coronary syndrome patients treated with ticagrelor (2015) (52)
- Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y12-Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y12 Inhibition to Prevent Subsequent Neointima* (2010) (51)
- Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2014) (50)
- Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. (2014) (50)
- Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST (2012) (50)
- Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes (2019) (49)
- Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns (2016) (48)
- Stabilizing Role of Platelet P2Y12 Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques (2010) (47)
- How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer? (2015) (46)
- Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. (2012) (46)
- Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors (2011) (46)
- Nonculprit Lesion Plaque Morphology in Patients With ST-Segment–Elevation Myocardial Infarction (2020) (45)
- Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. (2014) (45)
- Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses (2005) (44)
- Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. (2015) (43)
- Antiplatelet therapy in cardiovascular disease (2004) (41)
- Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans (2018) (41)
- Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes (2014) (41)
- ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial: Insights From the ECG Substudy (2012) (41)
- Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
- Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes (2005) (41)
- Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. (2016) (39)
- Laboratory investigation of platelet function. (1999) (38)
- Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). (2013) (38)
- Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel (2010) (37)
- Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (2016) (36)
- Platelet function testing in atherothrombotic disease. (2012) (35)
- Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. (2020) (35)
- Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding? (2014) (33)
- Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations (2014) (33)
- Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro (2016) (32)
- Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention (2004) (32)
- Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. (2018) (31)
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease (2009) (31)
- Platelet function testing and prediction of procedural bleeding risk (2013) (31)
- Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 (2019) (31)
- Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes (2017) (30)
- Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease (2012) (30)
- Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis. (2015) (30)
- Clopidogrel in acute coronary syndrome: to genotype or not? (2009) (30)
- Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosis (2015) (29)
- Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial (2012) (29)
- Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes (2018) (28)
- Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. (2017) (28)
- Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54 (2016) (28)
- Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. (2013) (27)
- Monitoring Antiplatelet Therapy (2017) (27)
- Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes (2014) (27)
- Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial (2021) (26)
- Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial (2019) (25)
- Development and clinical use of prasugrel and ticagrelor. (2012) (24)
- New P2Y12 inhibitors (2011) (24)
- Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. (2016) (23)
- C-X-C Ligand 16 Is an Independent Predictor of Cardiovascular Death and Morbidity in Acute Coronary Syndromes. (2019) (23)
- Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels (2020) (23)
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome (2019) (23)
- Humor and sexual selection (2003) (23)
- Antiplatelet therapy and vascular disease: an update (2010) (22)
- Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding (2017) (22)
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study) (2018) (22)
- Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study. (2013) (22)
- Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study (2020) (22)
- Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial (2020) (22)
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. (2020) (22)
- Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Results From the PEGASUS-TIMI 54 Trial. (2017) (22)
- Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. (2005) (21)
- Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine (2018) (21)
- Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status (2017) (21)
- Pierrots on the Stage of Desire: Nineteenth-Century French Literary Artists and the Comic Pantomime (1985) (21)
- Dyspnea related to reversibly-binding P2Y12 inhibitors: A review of the pathophysiology, clinical presentation and diagnostics. (2016) (20)
- NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO) (2015) (20)
- Use of glycoprotein IIb/IIIa antagonists to prevent stent thrombosis in morphine-treated patients with ST-elevation myocardial infarction (2020) (20)
- Polymorphism of the cystatin C gene in patients with acute coronary syndromes: Results from the PLATelet inhibition and patient Outcomes study. (2014) (20)
- Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. (2019) (19)
- Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: Findings from the EPICOR study (2015) (18)
- Antithrombotic therapy in diabetes: which, when, and for how long? (2021) (18)
- Comparison of P2Y12 inhibitors for mortality and stent thrombosis in patients with acute coronary syndromes: Single center study of 10 793 consecutive ‘real-world’ patients (2017) (18)
- Impact of Aspirin Dosing on the Effects of P2Y12 Inhibition in Patients with Acute Coronary Syndromes (2014) (18)
- Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). (2014) (18)
- Meta‐analysis of echocardiographic quantification of left ventricular filling pressure (2020) (18)
- PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact (2015) (18)
- Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis (2017) (17)
- Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention (2012) (17)
- Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes (2014) (17)
- Population pharmacokinetics of ticagrelor in patients with acute coronary syndromes. (2016) (17)
- Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease? (2010) (17)
- Admission Levels of DKK1 (Dickkopf-1) Are Associated With Future Cardiovascular Death in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial (2019) (17)
- Platelets: Developmental biology, physiology, and translatable platforms for preclinical investigation and drug development (2008) (17)
- Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial (2009) (17)
- Variability of response to antiplatelet therapy (2008) (16)
- Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome (2017) (16)
- EFFICACY AND SAFETY OF TICAGRELOR AS LONG-TERM SECONDARY PREVENTION IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION AND PERIPHERAL ARTERY DISEASE (2016) (16)
- Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial (2019) (16)
- Design and rationale of the COMPLETE trial: A randomized, comparative effectiveness study of complete versus culprit-only percutaneous coronary intervention to treat multivessel coronary artery disease in patients presenting with ST-segment elevation myocardial infarction. (2019) (16)
- Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? (2019) (16)
- Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–ST‐segment elevation acute coronary syndrome in the PLATO trial (2017) (15)
- Ticagrelor: Effects Beyond the P2Y12 Receptor. (2017) (15)
- Studies of the interaction of ticagrelor with the P2Y13 receptor and with P2Y13-dependent pro-platelet formation by human megakaryocytes (2016) (15)
- The IL-1RI Co-Receptor TILRR (FREM1 Isoform 2) Controls Aberrant Inflammatory Responses and Development of Vascular Disease (2017) (15)
- REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL (2016) (15)
- Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors. (2016) (15)
- Cangrelor for the management and prevention of arterial thrombosis (2016) (15)
- Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. (2020) (14)
- Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy (2014) (14)
- Interleukin‐18 in patients with acute coronary syndromes (2019) (14)
- Response to Letter Regarding Article, “Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO” (2012) (14)
- Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54 (2015) (14)
- Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition (2020) (14)
- Association of the coronary artery disease risk gene GUCY1A3 with ischaemic events after coronary intervention. (2019) (14)
- Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. (2017) (14)
- Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. (2020) (13)
- Conservation Theology for Conservation Biologists—a Reply to David Orr (2005) (13)
- Novel approaches to P2Y12 inhibition and aspirin dosing (2020) (13)
- Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction (2021) (13)
- Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy (2017) (13)
- Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgery. (2011) (13)
- Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients (2018) (12)
- Antithrombotic Therapy after Percutaneous Coronary Intervention of Bifurcation Lesions. (2020) (12)
- Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrel (2014) (12)
- The future of P2Y12 receptor antagonists (2015) (12)
- Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. (2015) (11)
- The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial (2020) (11)
- Antithrombotic Agents: From Aspirin to DOACs in Coronary Artery Disease and in Atrial Fibrillation (Part I). (2019) (11)
- Genetics of response to antiplatelet therapy. (2014) (11)
- Electrocardiogram Interpretation as a Basis for Thrombolysis (1997) (11)
- Pentraxin-3 vs C-reactive protein and other prognostic biomarkers in acute coronary syndrome: A substudy of the Platelet Inhibition and Patients Outcomes (PLATO) trial (2020) (11)
- Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay (2013) (11)
- P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention (2022) (11)
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study (2017) (11)
- New developments in antiplatelet therapy (2008) (10)
- Ticagrelor: from concept to clinical evaluation. (2011) (10)
- Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial (2020) (10)
- Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial (2019) (10)
- Can we improve the efficacy of low-dose aspirin? (2014) (10)
- Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y 12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes (2007) (10)
- Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. (2015) (10)
- Antithrombotic therapy for patients with chronic coronary syndromes (2020) (10)
- The right oral antithrombotics in acute coronary syndromes (2009) (9)
- Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction . (2017) (9)
- IMPACT OF MORPHINE ADMINISTRATION ON TICAGRELOR-INDUCED PLATELET INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED BY PRIMARY PCI: RESULTS FROM THE PRIVATE-ATLANTIC STUDY (2015) (9)
- Pierrot, a Critical History of a Mask (1978) (9)
- Glycosylated apolipoprotein J in cardiac ischaemia: molecular processing and circulating levels in patients with acute ischaemic events. (2021) (9)
- Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial (2019) (9)
- TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS (2014) (9)
- Ticagrelor: agonising over its mechanisms of action. (2016) (8)
- International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests (2021) (8)
- Ticagrelor in patients with heart failure after acute coronary syndromes-Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. (2019) (8)
- Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. (2012) (8)
- New Antithrombotic Drugs in Acute Coronary Syndrome (2020) (8)
- Abstract 12092: Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO (2010) (8)
- The long journey of individualizing antiplatelet therapy after acute coronary syndromes. (2020) (8)
- Efficacy and Safety of Ticagrelor as Long-Term Secondary Prevention in Patients with Peripheral Artery Disease and Prior Myocardial Infarction (2016) (8)
- Duration of ischemia and treatment effects of pre‐ versus in‐hospital ticagrelor in patients with ST‐segment elevation myocardial infarction: Insights from the ATLANTIC study (2018) (8)
- Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial (2016) (7)
- TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL (2013) (7)
- Thrombogenicity and Antithrombotic Strategies in Structural Heart Interventions and Nonaortic Cardiac Device Therapy—Current Evidence and Practice (2019) (7)
- Abstract 5901: The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study (2009) (7)
- Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy (2021) (7)
- I am i because my little dog knows me: Prolegomenon to a theory of mimesis (1990) (7)
- Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. (2019) (7)
- Pierrots on the stage of desire (1985) (7)
- EFFICACY AND SAFETY OF TICAGRELOR FOR LONG-TERM SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH PRIOR MI AND MULTIVESSEL CORONARY DISEASE: INSIGHTS FROM THE PEGASUS-TIMI 54 TRIAL (2016) (7)
- Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. (2019) (7)
- Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial (2018) (7)
- Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit? (2020) (7)
- Antithrombotics (2019) (7)
- Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease (2020) (6)
- Plaque Burden and 1-Year Outcomes in Acute Chest Pain: Results From the Multicenter RAPID-CTCA Trial. (2022) (6)
- Ticagrelor: clinical development and future potential. (2021) (6)
- Aspirin and Primary Prevention in Patients with Diabetes—A Critical Evaluation of Available Randomized Trials and Meta-Analyses (2019) (6)
- Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. (2013) (6)
- Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. (2013) (6)
- Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis (2018) (6)
- TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54 (2015) (6)
- More transparency for a therapeutic window in platelet P2Y12 inhibition? (2015) (6)
- Exposure‐Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction (2017) (6)
- Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention (2006) (6)
- TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY (2010) (6)
- Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist (2020) (6)
- INHIBITION OF THROMBOSIS BY AZD6140 VIA SELECTIVE BLOCKADE OF THE P2Y12 RECEPTOR IN A MURINE LASER-INJURY MODEL (2007) (6)
- Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute CardioVascular Care and the European Society of Cardiology Working Group on Thrombosis. (2020) (6)
- ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). (2011) (6)
- Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus (2016) (6)
- Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention (2020) (5)
- Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. (2017) (5)
- Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial. (2020) (5)
- Pre‐hospital administration of ticagrelor in diabetic patients with ST‐elevation myocardial infarction undergoing primary angioplasty: A sub‐analysis of the ATLANTIC trial (2018) (5)
- Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. (2019) (5)
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. (2018) (5)
- Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent (2022) (5)
- Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk (2020) (5)
- Sunday, 26 August 2012 (2012) (5)
- Antiplatelet therapy: Cangrelor succeeds, at last, in PCI (2013) (5)
- Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake (2020) (5)
- Complete Revascularization vs Culprit Lesion-Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial. (2022) (5)
- The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia (2011) (5)
- Platelets and the Endothelium (2021) (5)
- Regional variation in patients and outcomes in the GLOBAL LEADERS trial. (2020) (5)
- Next-Generation Sequencing of CYP2C19 in Stent Thrombosis: Implications for Clopidogrel Pharmacogenomics (2020) (4)
- Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery—a systematic review (2022) (4)
- Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period (2015) (4)
- Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS‐TIMI 54 Trial (2020) (4)
- ST Elevation Acute Coronary Syndromes in PLATO: Insights from the ECG Substudy (2011) (4)
- Ticagrelor versus prasugrel for PCI-managed myocardial infarction: the battle of the giants continues (2021) (4)
- Opiates and Clopidogrel Efficacy: Lost in Transit? (2020) (4)
- ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. (2019) (4)
- A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia (2020) (4)
- Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. (2017) (4)
- Clinical Perspectives and Pearls from the 2015 ESC NSTE-ACS Guidelines (2016) (4)
- Combining DAPT with a PPI faces the acid test of real-world use. (2019) (4)
- BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes (2016) (4)
- Coronary Heart Disease Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention (2010) (4)
- Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy (2020) (4)
- THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL (2010) (4)
- Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial (2021) (3)
- Contemporary Management of ST-Segment Elevation Myocardial Infarction (2012) (3)
- Abstract 12851: Osteoprotegerin is Associated With Major Bleeding but Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes - Insights From the PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2016) (3)
- COMPLETE VERSUS CULPRIT-LESION-ONLY REVASCULARIZATION FOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: A COLLABORATIVE META-ANALYSIS OF RANDOMIZED TRIALS (2020) (3)
- Abstract 14299: Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial (2011) (3)
- A Biocultural Approach to Literary Theory and Interpretation (2013) (3)
- What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus? (2010) (3)
- Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". (2014) (3)
- Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial. (2021) (3)
- Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54. (2022) (3)
- TICAGRELOR VERSUS CLOPIDOGREL IN WOMEN WITH ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (3)
- 215 Ticagrelor Inhibits Release of Pro-inflammatory Cytokines TNF and IL-6 during Human Endotoxaemia (2014) (3)
- Thrombosis and antithrombotic therapy Ischaemic risk and efficacy of ticagrelor in relation to time from P 2 Y 12 inhibitor withdrawal in patients with prior myocardial infarction : insights from PEGASUS-TIMI 54 (2016) (3)
- ROLE OF ADMISSION CARDIAC BIOMARKERS IN RISK STRATIFICATION OF PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL (2014) (3)
- REDUCTION IN PULMONARY ADVERSE EVENTS AND ASSOCIATED SEPSIS AND MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS TREATED WITH TICAGRELOR COMPARED TO CLOPIDOGREL: A POST HOC ANALYSIS OF THE PLATO STUDY (2012) (3)
- P3670Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 (2017) (3)
- Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions (2022) (3)
- Platelets and the Endothelium: Active Participants in Severe COVID-19 Infection (2021) (3)
- Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients’ value (2014) (3)
- Monday, 27 August 2012 (2012) (3)
- Abstract 5494: Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Coronary Artery Disease (2009) (3)
- Choosing a perspective on mortality with DAPT. (2015) (3)
- Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial (2020) (3)
- The cardiac complications of COVID-19: many publications, multiple uncertainties (2020) (2)
- THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS (2013) (2)
- Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction (2020) (2)
- Art and Religion: Co-Evolved Phenomena (2008) (2)
- Education in atherothrombosis (2011) (2)
- Availability of cath lab facilities and contemporary inter-hospital transfer patterns for the management of ACS patients : findings from the EPICOR study (2012) (2)
- Acute, periprocedural and longterm antithrombotic therapy in older adults. (2022) (2)
- 72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery (2017) (2)
- CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial (2013) (2)
- Abstract 17121: Reduction in Total Cardiovascular Events With Long-term Use of Ticagrelor in Patients With Prior Myocardial Infarction in the PEGASUS-TIMI 54 Trial (2015) (2)
- Balancing the risk of ischaemic and bleeding events in ACS (2015) (2)
- Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes (2013) (2)
- Dual antiplatelet therapy in the ‘real world’ (2018) (2)
- Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. (2021) (2)
- 2349Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients (2019) (2)
- Ticagrelor monotherapy in CKD: better safety at what price? (2021) (2)
- Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. (2022) (2)
- Platelets in Acute Coronary Syndromes (2017) (2)
- Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLA (2012) (2)
- Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. (2019) (2)
- The challenges of antithrombotic therapy in patients with left ventricular thrombosis (2018) (2)
- The Pantomime of Jean-Gaspard Deburau at the Théâtre des Funambules (1819–1846) (1982) (2)
- Abstract 11449: Morphine Delays the Onset of Action of Prasugrel in Patients With Prior History of St Elevation Myocardial Infarction (2013) (2)
- Thrombotic response (2018) (2)
- Abstract 3292: AZD6140 Exerts Greater Inhibition of Platelet Aggregation than Clopidogrel in Patients with Stable Atherosclerotic Disease or Unstable Coronary Disease (2006) (2)
- P2Y12 RECEPTOR INHIBITION ACCORDING TO PREHOSPITAL ADMINISTRATION OF TICAGRELOR IN PRIMARY PCI FOR ST ELEVATION MYOCARDIAL INFARCTION: THE PRIVATE-ATLANTIC STUDY (2015) (2)
- Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE? (2021) (2)
- Outcomes with ticagrelor versus clopidogrel in relation to high sensitivity troponin-T in non-ST-elevation acute coronary syndrome patients managed with early invasive or non-invasive treatment : a substudy from the prospective randomized PLATelet inhibit (2013) (2)
- Current regional differences in the use of antiplatelet drugs for the treatment of acute coronary syndromes: results from the EPICOR study (2012) (2)
- Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach (2020) (2)
- Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS (2018) (2)
- Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? : - A Report From the Plato Gwas Study (2013) (1)
- ULTRA-LOW-DOSE TWICE-DAILY ASPIRIN IMPROVES HEMOSTASIS AND MAINTAINS PLATELET INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING TICAGRELOR (2018) (1)
- Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y12 Receptor Inhibiting Therapies". (2018) (1)
- Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial (2022) (1)
- GDF-15 level in acute coronary syndrome and its relations to cardiovascular risk factors, disease manifestations, treatments and outcome - results from the PLATO-study (2013) (1)
- Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose (2013) (1)
- O4 Heparins sensitize platelets to responses mediated via both the P27 and the P2Y1 receptor pathways (1999) (1)
- TICAGRELOR INHIBITS CHANGES IN FIBRIN CLOT STRUCTURE INDUCED BY BACTERIAL ENDOTOXEMIA (2015) (1)
- USEFULNESS OF BIOMARKERS FOR PROGNOSTICATION OF OUTCOME WITH EARLY INVASIVE OR NONINVASIVE TREATMENT IN NON-ST-ELEVATION ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (1)
- Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment–Elevation Myocardial Infarction (2021) (1)
- Reply: Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet. (2015) (1)
- Clinical experience with antithrombotic drugs acting on purine receptor pathways (2001) (1)
- Abstract 15029: Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes and History of Stroke or Transient Ischemic Accident: Results from the Platelet Inhibition and Patient Outcomes Trial (2011) (1)
- Pharmacology and clinical trials of reversibly-binding P 2 Y 12 inhibitors (2017) (1)
- Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial (2022) (1)
- Reply: Cost-Effectiveness of Long-Term Ticagrelor in Patients With Prior Myocardial Infarction: Analysis by Subgroups. (2018) (1)
- Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial (2022) (1)
- Chemokine (CXC motif) ligand 16 (CXCL16) and osteoprotegerin (OPG) as predictors of outcome in patients with acute coronary syndromes (ACS) a PLATO biomarker substudy (2014) (1)
- LONG-TERM SAFETY OF TICAGRELOR MONOTHERAPY IN PATIENTS UNDERGOING PCI FOR STABLE CORONARY ARTERY DISEASE IN THE GLOBAL LEADERS STUDY: IMPACT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2019) (1)
- RELATIONSHIP BETWEEN NONSUSTAINED VENTRICULAR TACHYCARDIA AND VASCULAR DEATH IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2012) (1)
- Inhibition and Patient Outcomes (PLATO) Trial In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet ST-Elevation Acute Coronary Syndrome Patients Managed With or Without − Non Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in (2014) (1)
- Health economic evalatuion of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes (ACS) intended for non-invasive management based on the PLATO trial (2013) (1)
- Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. (2022) (1)
- Activated Leukocyte Cell Adhesion Molecule (ALCAM) And Outcomes In Acute Coronary Syndromes : A Plato Biomarker Substudy (2015) (1)
- Abstract 5495: More Rapid and Consistent Inhibition of Platelet Aggregation is Achieved by Loading With Ticagrelor Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy (2009) (1)
- REDUCTION IN FIRST AND RECURRENT CARDIOVASCULAR AND ISCHEMIC EVENTS WITH TICAGRELOR COMPARED WITH CLOPIDOGREL IN THE PLATO STUDY (2012) (1)
- CONSISTENT BENEFIT OF TICAGRELOR COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS REGARDLESS OF BASELINE INFLAMMATORY MARKERS (2012) (1)
- 27 Impact of Culprit Versus Non-Culprit Angiography Strategy on Primary PCI Door to Balloon Times (2016) (1)
- Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". (2013) (1)
- Abstract 20657: Plasma MicroRNAs Correlate With Platelet Reactivity in Patients With Acute Coronary Syndrome: Association With Platelet Function (2014) (1)
- 265 PLASMA MICRORNAS AS BIOMARKERS FOR PLATELET INHIBITION (2013) (1)
- Abstract 11821: An International Perspective of Current Patterns of Antiplatelet Drug Use in Acute Coronary Syndrome Patients. Results from the EPICOR Study (2012) (1)
- Resumption of Antiplatelet Therapy after Major Bleeding (2022) (1)
- Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54 (2015) (1)
- Greater efficacy of ticagrelor compared to clopidogrel in acute coronary syndrome is not driven by outcomes in poor metabolizers of clopidogrel (2012) (1)
- 2864Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (2017) (1)
- Abstract 13713: Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study (2013) (1)
- Corrigendum to “Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?” [Pharmacol. Ther. 127(2) (2010) 95–107] (2010) (1)
- Aproximación comparativa inicial en resultados del WISC-III v.ch. entre una muestra de jóvenes escolarizados pertenecientes a zonas rurales de la XV Región de Arica y Parinacota y la norma nacional (2016) (1)
- Jackson I. Cope, Dramaturgy of the Daemonic: Studies in Antigeneric Theatre from Ruzante to Grimaldi . Baltimore and London: The Johns Hopkins University Press, 1984. xii + 166 pp. $20.00. (1986) (1)
- CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS) (2011) (1)
- Abstract 4947: Maintenance Treatment With Ticagrelor Yields Greater and More Consistent Inhibition of Platelet Function Compared to Clopidogrel in Patients With Acute Coronary Syndromes: Results From the PLATO PLATELET Substudy (2009) (1)
- Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease (2020) (1)
- Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study (2018) (1)
- Treatment and prognosis of elderly patients with non-ST-elevation myocardial infarction (2022) (0)
- III. Gilles and Clown (1987) (0)
- II. Paul Legrand, Champfleury, and Pantomime after Deburau (1985) (0)
- Abstract 13389: High-Sensitivity Cardiac Troponin at Any Detectable Concentration Identifies Higher Risk of Major Cardiovascular Events in Patients With Stable Ischemic Heart Disease (2018) (0)
- SYNERGY- EVEROLIMUS ELUTING STENT WITH A BIOABSORBABLE POLYMER IN ST ELEVATION MYOCARDIAL INFARCTION- CLEAR SYNERGY OASIS-9 TRIAL (2022) (0)
- COMPLETE REVASCULARIZATION IN PATIENTS UNDERGOING A PHARMACOINVASIVE STRATEGY FOR STEMI (2021) (0)
- Serial cystatin C measurements and changes in glomerular filtration rate as predictors for death or myocardial infarction in ACS patients (2012) (0)
- I. Origins and Birth (1987) (0)
- III. In Pursuit of Colombine: Charles Nodier and Charles Baudelaire (1985) (0)
- Mononuclear cell recruitment and maturation to foam cells (2017) (0)
- P6411Dyspnea in ticagrelor treated patients in the all-comer randomized GLOBAL LEADERS study and its association with clinical outcomes (2019) (0)
- ’ s response to reviews Title : Prognostic value of frailty in elderly patients with acute coronary syndrome : A systematic review and meta-analysis (2019) (0)
- Anticoagulants, antiplatelets and thrombolytics (2004) (0)
- POS10 Variability in patient response to clopidogrel and effects on outcome from carotid stenting (2010) (0)
- Abstract 12530: Sustained P2Y12 Receptor Inhibition is Required to Effectively Inhibit Neointima Formation in a Murine Vascular Injury Model (2010) (0)
- Evaluation of the Effect of Interleukin 18 Associated Genetic Polymorphisms on Risk of Cardiovascular Events in Patients With Acute Coronary Syndrome (2013) (0)
- Abstract 5768: The Effect of Ticagrelor on Cardiopulmonary Function in Patients With Stable Coronary Artery Disease (2009) (0)
- Acute Coronary Syndromes PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRA·CER TRIAL (2012) (0)
- 51 Adherence to cardiologist recommendations regarding extended duration of ticagrelor for patients undergoing PCI for myocardial infarction (2020) (0)
- Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi‐country observational study (2021) (0)
- YIA6: VESSEL WALL, BUT NOT PLATELET, P2Y12 CONTRIBUTES TO EARLY ATHEROGENESIS (2013) (0)
- Bibliography of Principal Works Consulted (1987) (0)
- Romantic Adolescence: The Nineteenth Century (2017) (0)
- VIII. Pierrot oedipien: J.-Κ. Huysmans (1985) (0)
- SERUM URIC ACID IS ASSOCIATED WITH CARDIOVASCULAR OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: RESULTS FROM THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2016) (0)
- PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL (2016) (0)
- Multicentre Study of the P 2 T Receptor Antagonist AR-C 69931 MX Assessing Safety , Tolerability and Activity in Patients with Acute Coronary Syndromes (2018) (0)
- Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y 12 receptor antagonist, in patients with chronic coronary syndromes Thrombosis and antithrombotic therapy (2020) (0)
- TICAGRELOR POTENTIATES NEUTROPHIL PHAGOCYTOSIS VIA INHIBITION OF ADENOSINE REUPTAKE BY ERYTHROCYTES (2015) (0)
- Development of a novel biomarker-based clinical prediction model for major adverse cardiovascular events in revascularized patients with acute coronary syndromes (2015) (0)
- Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age? (2019) (0)
- Abstract 20470: Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes (2014) (0)
- Early computed tomography coronary angiography in adults presenting with suspected acute coronary syndrome: the RAPID-CTCA RCT. (2022) (0)
- Abstract 16792: Incidence and Predictors of Stent Thrombosis: A Review of 5,834 Consecutive Patients in a Single UK Centre (2012) (0)
- Abstract 14143: Caffeine and Dyspnea With Ticagrelor: A Sub-Analysis From PEGASUS TIMI-54 Trial (2018) (0)
- Impact of Medication on Quantification of Plasma MicroRNAs in Patients With Cardiovascular Disease (2013) (0)
- TCT-36 Complete Revascularization Versus Culprit Lesion–Only PCI in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease: A Subgroup Analysis of the COMPLETE Trial (2022) (0)
- Relationship between ATP hydrolysis and molecular dynamics in co-freeze-dried sugar-ATP mixtures (2010) (0)
- Abstract 14161: Long-Term Secondary Prevention With Ticagrelor for Prior Myocardial Infarction in Patients With No Coronary Stenting: A Sub-Analysis From PEGASUS TIMI 54 (2018) (0)
- Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention (2022) (0)
- B β Arg 448 Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes (2018) (0)
- THE PROGNOSTIC VALUE OF PLAQUE IN PATIENTS WITH ACUTE CHEST PAIN (2022) (0)
- RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL (2014) (0)
- 203 Ticagrelor and Clopidogrel Attenuate the Prothrombotic State induced by Bacterial Endotoxaemia (2015) (0)
- GuidelinesESC/EAS Guidelines for the Management of Dyslipidaemias (2013) (0)
- Steen Elkjær Husted MD FESC 1950-2016. (2017) (0)
- Secreted wingless (Wnt) antagonists and risk prediction in acute coronary syndrome (ACS) a PLATO biomarker substudy (2014) (0)
- Book Review:Symbolist Theater: The Formation of an Avant-Garde Frantisek Deak (1996) (0)
- TCT-35 Effects of Complete Revascularization According to Age in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel: Insights From the COMPLETE Trial (2022) (0)
- Abstract 5762: A Randomized Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients With Stable Coronary Artery Disease (2009) (0)
- CORONARY INTERVENT IONS (2015) (0)
- Ascertainment , classification , and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs . clopidogrel following acute coronary syndrome (2015) (0)
- Ischaemic events following planned discontinuation of study treatment with ticagrelor or clopidogrel in the PLATO study (2013) (0)
- Rifampicin increases the extent of P2Y12 receptor blockade achieved by clopidogrel administration (2009) (0)
- ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2011) (0)
- Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding. (2023) (0)
- Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease: 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Association for Acute CardioVascular Care (ACVC) and European Association of Pr (2023) (0)
- This is a repository copy of Antithrombotic therapy after acute coronary syndrome or PCI (2019) (0)
- Successful reperfusion is associated with lower levels of markers of myocardial damage and dysfunction in ST-elevation but not in non-ST-elevation myocardial infarction: insights from the PLATO trial (2016) (0)
- PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL (2012) (0)
- Stroke Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack (2012) (0)
- Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries (2021) (0)
- TCT-404 Benefit and Risks of Aspirin on Top of Ticagrelor in Acute Coronary Syndromes: Insights From the Randomized GLOBAL LEADERS Trial (2019) (0)
- Original Research: Focus on Platelets Ticagrelor Effectively and Reversibly Blocks Murine Platelet P2Y 12 -Mediated Thrombosis and Demonstrates a Requirement for Sustained P2Y 12 Inhibition to Prevent Subsequent Neointima* (2010) (0)
- Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial (2022) (0)
- Clinical Investigations Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel (2010) (0)
- High-performance liquid chromatography method development for studying the degradation of freeze-dried adenosine triphosphate when stored at 4 and 40 degrees C. (2009) (0)
- Randomised Controlled Trial of Early CT Coronary Angiography in Patients With Suspected Acute Coronary Syndrome (2020) (0)
- BArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes (2018) (0)
- THROMBOINFLAMMATORY RESPONSE TO ON-PUMP CORONARY ARTERY BYPASS GRAFT SURGERY LEADS TO IMPAIRED PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROME (2022) (0)
- Mean platelet volume and platelet count in acute coronary syndrome patients: role of a genetic variants on chr7q22.3 and chr3p13-p21 P4881 | BEDSIDE Modulation of complement C3 levels and fibrin clot structure: the role of aspirin dose (0)
- Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial (2013) (0)
- BArg 448 Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes (2016) (0)
- Platelet Physiology and the Role of the Platelet in Ischemic Heart Disease (2009) (0)
- P4404Impaired fibrin clot lysis persists at 1 month post ACS: a PLATO substudy (2018) (0)
- Pierrot: A Critical Study of a Mask (1981) (0)
- Ticagrelor: novel antithrombotic for acute coronary syndromes (2011) (0)
- ' s response to reviews Title : Gene sequence variations of the platelet P 2 Y 12 receptor are associated with coronary artery disease (2007) (0)
- PERFORMANCE OF A NOVEL GENETIC RISK SCORE TO IDENTIFY RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CARDIOMETABOLIC DISEASE (2020) (0)
- A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control (2021) (0)
- INHIBITORY MECHANISMS OF VERY LOW DOSE RIVAROXABAN IN NON-ST-ELEVATION MYOCARDIAL INFARCTION (2018) (0)
- Beware the normal angiogram. (2014) (0)
- APIXABAN VERSUS WARFARIN AND ASPIRIN VERSUS PLACEBO ACCORDING TO RENAL FUNCTION AFTER ACUTE CORONARY SYNDROME OR PCI IN ATRIAL FIBRILLATION: INSIGHTS FROM THE AUGUSTUS TRIAL (2020) (0)
- TCT-201 Impact of Proton Pump Inhibitors on Efficacy of Antiplatelet Strategies With Ticagrelor or Aspirin After Percutaneous Coronary Intervention (2021) (0)
- X. Pierrot Vanishes: Paul Margueritte and Stéphane Mallarmé (1985) (0)
- II. L'Education Foraine: The Eighteenth Century (1987) (0)
- Genotype Studies Patients Treated With Ticagrelor Versus Clopidogrel : The ONSET / OFFSET and Genotype and Pharmacodynamics in CYP 2 C 19 First Analysis of the Relation Between on the World Wide Web (2010) (0)
- CLINICAL CORRELATES OF ISCHEMIC AND BLEEDING RISK IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION TREATED WITH EXTENDED DUAL ANTIPLATELET THERAPY WITH TICAGRELOR 60 MG: INSIGHTS FROM ALETHEIA, A MULTI-COUNTRY OBSERVATIONAL STUDY (2022) (0)
- Biomarker Concentrations and Their Temporal Changes in Patients With Myocardial Infarction and Nonobstructive Compared With Obstructive Coronary Arteries: Results From the PLATO Trial (2022) (0)
- Monitoring the Effects of Glycoprotein IIb/IIIa Antagonists using a Whole Blood Assay of Platelet Microaggregation: Comparison with Other Aggregation Methodologies (1999) (0)
- Abstract 11861: Number of Antithrombotic Drugs and Association with In-Hospital Clinical Outcomes in Patients with Acute Coronary Syndromes: Results from the EPICOR Study (2012) (0)
- Plasma microRNA levels in patients with acute coronary syndrome are associated with platelet function (2014) (0)
- XI. Epilogue: Eclipse (1985) (0)
- Prolonged prothrombotic effects of antecedent hypoglycemia in individuals with type 2 mellitus (2019) (0)
- Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial (2022) (0)
- Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. (2023) (0)
- Republished Education in Heart: New P2Y12 inhibitors (2011) (0)
- Abstract 20393: First Analysis of Relation Between CYP2C19 Genotype and Platelet Function in Ticagrelor versus Clopidogrel Treated Patients: Results from the ONSET/OFFSET and RESPOND Studies (2010) (0)
- The conundrum of simultaneous antiplatelet and anticoagulant therapy: how to solve it? (2021) (0)
- COMPARISON OF P2Y12 INHIBITORS FOR MORTALITY AND STENT THROMBOSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES: SINGLE CENTRE STUDY OF 10,793 CONSECUTIVE ‘REAL-WORLD’ PATIENTS (2017) (0)
- Guía ESC 2019 sobre el diagnóstico y tratamiento de los síndromes coronarios crónicos (2020) (0)
- Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis (2021) (0)
- Zebrafish as a model to investigate the roles of the p2y12 receptor in vivo (2012) (0)
- Handlist of Pantomime Scenarios (1985) (0)
- Abstract 13290: GDF-15 at One Month After an Acute Coronary Syndrome is Associated With Increased Risk of Major Bleeding - A PLATO Biomarker Substudy (2015) (0)
- VI. Pierrot Ephèbe: T. S. Eliot and Wallace Stevens (1987) (0)
- Selatogrel and other P2Y12 inhibitors' putative off-target effects. (2021) (0)
- Abstract 14539: Adverse Fibrin Clot Properties Are Associated With Worse Outcome Following Acute Coronary Syndrome: A PLATO Substudy (2017) (0)
- 113 Potential role of coronary physiology in treating ‘bystander’ disease in patients with ST-elevation myocardial infarction (2020) (0)
- The n e w e n g l a n d j o u r n a l of m e d i c i n e Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease (2017) (0)
- agonising over its mechanisms of action (2016) (0)
- CRT-200.62 The Impact of Ticagrelor on Platelet Reactivity in African Americans: Interim Results of the ACS Ethnicity Study (2016) (0)
- Prolonged Inflammatory Response Post-Hypoglycemia: Mechanistic Insights Into the Relationship Between Low Glucose and Cardiovascular Risk (2022) (0)
- P823Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert F. Storey?
Robert F. Storey is affiliated with the following schools:
